Long-term survival after conversion surgery for an esophageal neuroendocrine carcinoma: a case report

[1]  Y. Kodera,et al.  International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1) , 2021, Annals of gastroenterological surgery.

[2]  Y. Kakeji,et al.  Nationwide survey of neuroendocrine carcinoma of the esophagus: a multicenter study conducted among institutions accredited by the Japan Esophageal Society , 2021, Journal of Gastroenterology.

[3]  Fangwei Xu,et al.  Efficacy of conversion surgery on stage IV gastric cancer and its prognosis analysis. , 2020, Panminerva medica.

[4]  T. Okumura,et al.  Lymph Node Metastasis From Gastroesophageal Cancer Successfully Treated by Nivolumab: A Case Report of a Young Patient , 2019, Front. Oncol..

[5]  Kazuhiro Yoshida,et al.  Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors , 2019, Annals of surgery.

[6]  Japan Esophageal Society.  Japanese Classification of Esophageal Cancer, 11th Edition: part I , 2016, Esophagus.

[7]  K. Chìn,et al.  Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer , 2016, British Journal of Cancer.

[8]  Long-Qi Chen,et al.  Neuroendocrine carcinoma of the esophagus: clinical characteristics and prognostic evaluation of 49 cases with surgical resection. , 2016, Journal of Thoracic Disease.

[9]  H. Sorbye,et al.  ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas , 2016, Neuroendocrinology.

[10]  Y. Kodera,et al.  Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification , 2015, Gastric Cancer.

[11]  H. Kuwano,et al.  Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer , 2015, Annals of Surgical Oncology.

[12]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.